| Immune Response Following Seasonal Influenza Vaccination (NCT03163342) | Altimmune, Inc. | 2017-05-08 |
| Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (NCT03143101) | MedImmune LLC | 2017-05-08 |
| Safety Study of Live Attenuated Influenza Vaccine, CodaVax (NCT03926416) | Codagenix, Inc | 2017-02-21 |
| Impact of Rapid Flu Testing in BMC ED (NCT02979730) | Boston Medical Center | 2017-02-07 |
| A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia (NCT02972957) | London School of Hygiene and Tropical Medicine | 2017-01-30 |
| Evaluation of Moderate to Severe Influenza Outcomes in Children (NCT02979626) | University of Colorado, Denver | 2017-01-30 |
| Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications (NCT02949011) | Shionogi | 2017-01-11 |
| Study of an Investigational Monoclonal Antibody, VIS410, in Subjects With Uncomplicated Influenza A (NCT02989194) | Visterra, Inc. | 2017-01-06 |
| Prospective Analysis of Seasonal Influenza - Viral Transmission and Evolution in the City of Basel, Switzerland (NCT03010007) | University Hospital, Basel, Switzerland | 2017-01-01 |
| Clinical Performance of the Diassess Influenza A and B Test (NCT03035396) | Diassess Inc. | 2016-12-29 |
| Immunogenicity and Safety Evaluation of QIS in Healthy Subjects (NCT04101435) | Adimmune Corporation | 2016-12-28 |
| Prospective System Analysis of the Seasonal Influenza Virus Transmissions and Evolution in the City of Basel Basel (NCT03451656) | University Hospital, Basel, Switzerland | 2016-12-27 |
| A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza (NCT02954354) | Shionogi | 2016-12-08 |
| Protection From Influenza: Determining the Impact of Prior Infection (NCT03004040) | Health Sciences North Research Institute | 2016-12-01 |
| Phase 3 Trial of Serbian Seasonal Influenza Vaccine (NCT02935192) | Institute of Virology, Vaccines and Sera, Torlak | 2016-11-28 |
| Different Regimens in Influenza Postexposure Chemoprophylaxis in Children (NCT04297462) | Centre of Postgraduate Medical Education | 2016-11-17 |
| Evaluation of Free Air Portable Air Powered Respirator (NCT02487147) | Wake Forest University Health Sciences | 2016-11-14 |
| H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses (NCT02921997) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-11-07 |
| Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers (NCT03849560) | NPO Petrovax | 2016-11-01 |
| A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV) (NCT02964065) | Changchun BCHT Biotechnology Co. | 2016-11-01 |
| Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children (NCT02871206) | McMaster University | 2016-11-01 |
| Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA (NCT05297994) | St. Petersburg Research Institute of Vaccines and Sera | 2016-10-24 |
| Asymptomatic Flu Project (NCT02868658) | Hospices Civils de Lyon | 2016-10-04 |
| High Dose vs. Standard Influenza Vaccine in Adult SOT (NCT03139565) | University Health Network, Toronto | 2016-10-01 |
| Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI) (NCT03016143) | Research Institute for Biological Safety Problems | 2016-10-01 |
| Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab) (NCT03061955) | Wake Forest University Health Sciences | 2016-10-01 |
| Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers (NCT02955030) | Nitto Denko Corporation | 2016-10-01 |
| Immunogenicity of Influenza Vaccine in Long Term Care (NCT02933723) | Insight Therapeutics, LLC | 2016-10-01 |
| Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age (NCT02587221) | Seqirus | 2016-09-30 |
| Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel (NCT03331991) | Abt Associates | 2016-09-28 |
| Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children (NCT02915302) | Sanofi Pasteur, a Sanofi Company | 2016-09-23 |
| Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations (NCT02908269) | Sanofi Pasteur, a Sanofi Company | 2016-09-15 |
| Influenza Vaccine Attitudes, Intent, and Receipt: Pediatric (NCT02907580) | Columbia University | 2016-09-13 |
| Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease (NCT02883426) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-09-01 |
| 2-week dc of MTX and Influenza Vaccination in RA (NCT02897011) | Seoul National University Hospital | 2016-09-01 |
| High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant (NCT02860039) | Vanderbilt-Ingram Cancer Center | 2016-09-01 |
| A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine (NCT02918006) | Vaxart | 2016-08-31 |
| Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model (NCT03180801) | PepTcell Limited | 2016-08-18 |
| H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults (NCT02624219) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-08-16 |
| A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine (NCT02962908) | PepTcell Limited | 2016-08-01 |
| A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age (NCT02719743) | GlaxoSmithKline | 2016-07-07 |
| The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination (NCT02876159) | Emory University | 2016-07-01 |
| A Study to Assess the PK of AL-794 Formulations in Healthy Subjects (NCT02877160) | Alios Biopharma Inc. | 2016-06-30 |
| Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE) (NCT02762851) | McMaster University | 2016-06-01 |
| Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects (NCT03345043) | ModernaTX, Inc. | 2016-05-11 |
| Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season (NCT02743117) | MedImmune LLC | 2016-05-02 |
| Lingdancao Granules in the Treatment of Seasonal Influenza (NCT02662426) | The First Affiliated Hospital of Guangzhou Medical University | 2016-04-01 |
| Adjuvanted Influenza Vaccination in U.S. Nursing Homes (NCT02882100) | Insight Therapeutics, LLC | 2016-04-01 |
| The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years (NCT05126979) | St. Petersburg Research Institute of Vaccines and Sera | 2016-03-09 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age (NCT02177734) | GlaxoSmithKline | 2016-03-01 |
| Safety Study of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in Chinese Adults Aged 3 Years and Older (NCT02665871) | Beijing Chaoyang District Centre for Disease Control and Prevention | 2016-03-01 |
| XC8 in the Treatment of Patients With Acute Respiratory Viral Infection (NCT03441373) | PHARMENTERPRISES LLC | 2016-02-03 |
| Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989) (NCT02583256) | Seqirus | 2016-01-29 |
| H7N9 Boost in Healthy Adults (NCT02586792) | National Institute of Allergy and Infectious Diseases (NIAID) | 2016-01-12 |
| Extracorporeal Membrane Oxygenation in Coronavirus Disease (COVID-19), Influenza and ARDS of Other Ethiologies (NCT05353725) | University Medical Centre Ljubljana | 2016-01-01 |
| Effect of Drinking Fermented Milk on Immune Response (NCT02909842) | Mahidol University | 2016-01-01 |
| Health Status Prior and Post Infection With Influenza or COVID 19: a Population Based Retrospective Analysis of 2016-2021 (NCT05087355) | Medical University of Vienna | 2016-01-01 |
| Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o. (NCT02644018) | Valenta Pharm JSC | 2016-01-01 |
| A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older (NCT02710409) | Jiangsu Province Centers for Disease Control and Prevention | 2016-01-01 |
| Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination (NCT02485639) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-12-23 |
| A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza (NCT02603952) | MedImmune LLC | 2015-12-07 |
| Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza (NCT02612922) | Romark Laboratories L.C. | 2015-12-01 |
| Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects (NCT03076385) | ModernaTX, Inc. | 2015-12-01 |
| Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza (NCT02635724) | BioCryst Pharmaceuticals | 2015-12-01 |
| Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults (NCT02894840) | Mahidol University | 2015-11-01 |
| A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study (NCT02658409) | Green Cross Corporation | 2015-11-01 |
| ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir (NCT02609399) | Johns Hopkins University | 2015-11-01 |
| The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine (NCT02592486) | Kameda Medical Center | 2015-11-01 |
| Improving Influenza Vaccination Rates in Nurses Through Text Message Reminders : a RCT (NCT02589574) | The University of Hong Kong | 2015-11-01 |
| Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults (NCT02691130) | BiondVax Pharmaceuticals ltd. | 2015-11-01 |
| Comparison of Three Licensed Influenza Vaccines (NCT03068949) | University of Rochester | 2015-10-28 |
| Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry (NCT02554409) | Sanofi Pasteur, a Sanofi Company | 2015-10-13 |
| Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (UK) (NCT02567721) | GlaxoSmithKline | 2015-10-01 |
| T-cell Diversity Following Intranasal and Intramuscular Vaccines (NCT02557802) | University of Surrey | 2015-10-01 |
| Project IMPACT Immunizations (IMProving America's Communities Together) (NCT02584036) | American Pharmacists Association Foundation | 2015-10-01 |
| Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' (NCT02677493) | Il-Yang Pharm. Co., Ltd. | 2015-10-01 |
| Influenza Immunity in Children (NCT02559505) | University of Rochester | 2015-10-01 |
| Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain (NCT02423577) | Autoimmune Technologies, LLC | 2015-09-01 |
| Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years (NCT02550197) | Sanofi Pasteur, a Sanofi Company | 2015-09-01 |
| A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children (NCT02541253) | Green Cross Corporation | 2015-09-01 |
| Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults (NCT02563093) | Sanofi Pasteur, a Sanofi Company | 2015-09-01 |
| A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older (NCT02553343) | Sanofi Pasteur, a Sanofi Company | 2015-09-01 |
| Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (NCT02566265) | Yale University | 2015-09-01 |
| Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032) (NCT03023709) | Stanford University | 2015-09-01 |
| A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study (NCT02588521) | Alios Biopharma Inc. | 2015-08-31 |
| Household Transmission of Zoonotic Influenza Viruses in a Cohort of Egyptian Poultry Growers (NCT02459171) | St. Jude Children's Research Hospital | 2015-08-05 |
| Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children (NCT02539108) | Sanofi Pasteur, a Sanofi Company | 2015-08-01 |
| ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults (NCT02529904) | University of Oxford | 2015-08-01 |
| Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India (NCT02451358) | Sanofi Pasteur, a Sanofi Company | 2015-07-27 |
| Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older (NCT02464163) | Protein Sciences Corporation | 2015-07-01 |
| A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults (NCT02335164) | Vaxine Pty Ltd | 2015-07-01 |
| Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route) (NCT03546192) | Sanofi Pasteur, a Sanofi Company | 2015-06-17 |
| Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season (NCT02473510) | MedImmune LLC | 2015-06-01 |
| Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle (NCT02438423) | Mark Prausnitz | 2015-06-01 |
| A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China (NCT02269007) | Jiangsu Province Centers for Disease Control and Prevention | 2015-05-01 |
| Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years (NCT02434276) | VaxInnate Corporation | 2015-05-01 |
| Influenza Challenge Study of VIS410 in Healthy Volunteers (NCT02468115) | Visterra, Inc. | 2015-05-01 |
| Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above (NCT02369341) | GlaxoSmithKline | 2015-04-29 |
| Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers (NCT02385123) | National Institute of Allergy and Infectious Diseases (NIAID) | 2015-04-01 |
| Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics (NCT02154061) | Emory University | 2015-04-01 |